| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Reviva Pharmaceuticals Holdings, Inc.$0.41
+0.03 (+8.67%)
D 30Pipeline Score Fair Value Pharma · Clinical
Market Cap
4.51 M
EPS
-6.75
P/E Ratio
-
Value Trade
33.85 K
SEC Financials
Q1 2026Dilution Risk
35%R&D Expenses
1.44 M
Operating CF
-3.80 M
Total Assets
23.56 M
Total Liabilities
6.12 M
Equity
17.44 M
D/E Ratio
12,345
-58.48 %
Week
-55.77 %
1 Month
-93.33 %
3 Month
-96.61 %
6 Month
-99.62 %
5 Year
-99.82 %
All Time
Cash Data
Cash Position
22.19 M
Monthly Burn
1.27 M
Runway
15.8 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
82.20 K
52 Week Range
0.26 - 23.20
% held by Insiders
1.95 %
% held by Institutions
17.92 %
Enterprise Value
-9.52 M
Total Shares
115.03 M
Short %
0.5 %
Float Shares
98.81 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D30
Pipeline Score $5M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.2x
rNPV / MCap Top 34%
Micro Cap (rank 602 of 911)
Percentile RankReviva Pharmaceuticals Holdings, Inc. faces pipeline headwinds (30/100), with $429M risk-adjusted pipeline value, led by Brilaroxazine in Schizophrenia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brilaroxazine Small molecule | Schizophrenia | Phase 3 | NCT05184335 | 49% | $321M | RECRUITING | 690 | STALLED | D (25) | Feb 1, 2025 | MODERATE_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
brilaroxazine | schizophrenia | Phase 3 | 2026-04-23 | 50 mg of brilaroxazine vs. placebo, with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates lower than placebo Read More | Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications Read More | |
brilaroxazine | schizophrenia | Phase 3 | 2026-04-23 | 50 mg of brilaroxazine vs. placebo, with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates lower than placebo Read More | Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications Read More | |
brilaroxazine | schizophrenia | Phase 3 | 2026-04-23 | 50 mg of brilaroxazine vs. placebo, with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates lower than placebo Read More | Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RVPH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RVPH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How RVPH ranks across every disease it competes inCompetitive Position is a premium feature
See how RVPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial